Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer - A Randomized Clinical Study

G. Bolis, G. Bortolozzi, G. Carinelli, M. D'Incalci, F. Gramellini, L. Morasca, C. Mangioni

Research output: Contribution to journalArticle

Abstract

After intensive staging 74 ovarian cancer patients were randomized to two arms balanced for stage and post-surgery residual tumor. The two regimens were CTX 100 mg/day continuously and ADM 50 mg/m2 IV every 4 weeks plus CTX 100 mg/day. The response rates were respectively 42% and 52%. Median survival times were 13 and 14 months. The incidence of side effects was significantly higher in the combination-treatment arm. No other statistical differences were found.

Original languageEnglish
Pages (from-to)129-132
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume4
Issue number2
DOIs
Publication statusPublished - 1980

Fingerprint

Delta modulation
Residual Neoplasm
Ovarian Neoplasms
Doxorubicin
Cyclophosphamide
Surgery
Tumors
Survival
Incidence
Therapeutics
Clinical Studies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer - A Randomized Clinical Study. / Bolis, G.; Bortolozzi, G.; Carinelli, G.; D'Incalci, M.; Gramellini, F.; Morasca, L.; Mangioni, C.

In: Cancer Chemotherapy and Pharmacology, Vol. 4, No. 2, 1980, p. 129-132.

Research output: Contribution to journalArticle

Bolis, G. ; Bortolozzi, G. ; Carinelli, G. ; D'Incalci, M. ; Gramellini, F. ; Morasca, L. ; Mangioni, C. / Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer - A Randomized Clinical Study. In: Cancer Chemotherapy and Pharmacology. 1980 ; Vol. 4, No. 2. pp. 129-132.
@article{4fa27f7221334044a4a634d7b5a958a8,
title = "Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer - A Randomized Clinical Study",
abstract = "After intensive staging 74 ovarian cancer patients were randomized to two arms balanced for stage and post-surgery residual tumor. The two regimens were CTX 100 mg/day continuously and ADM 50 mg/m2 IV every 4 weeks plus CTX 100 mg/day. The response rates were respectively 42{\%} and 52{\%}. Median survival times were 13 and 14 months. The incidence of side effects was significantly higher in the combination-treatment arm. No other statistical differences were found.",
author = "G. Bolis and G. Bortolozzi and G. Carinelli and M. D'Incalci and F. Gramellini and L. Morasca and C. Mangioni",
year = "1980",
doi = "10.1007/BF00254034",
language = "English",
volume = "4",
pages = "129--132",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer - A Randomized Clinical Study

AU - Bolis, G.

AU - Bortolozzi, G.

AU - Carinelli, G.

AU - D'Incalci, M.

AU - Gramellini, F.

AU - Morasca, L.

AU - Mangioni, C.

PY - 1980

Y1 - 1980

N2 - After intensive staging 74 ovarian cancer patients were randomized to two arms balanced for stage and post-surgery residual tumor. The two regimens were CTX 100 mg/day continuously and ADM 50 mg/m2 IV every 4 weeks plus CTX 100 mg/day. The response rates were respectively 42% and 52%. Median survival times were 13 and 14 months. The incidence of side effects was significantly higher in the combination-treatment arm. No other statistical differences were found.

AB - After intensive staging 74 ovarian cancer patients were randomized to two arms balanced for stage and post-surgery residual tumor. The two regimens were CTX 100 mg/day continuously and ADM 50 mg/m2 IV every 4 weeks plus CTX 100 mg/day. The response rates were respectively 42% and 52%. Median survival times were 13 and 14 months. The incidence of side effects was significantly higher in the combination-treatment arm. No other statistical differences were found.

UR - http://www.scopus.com/inward/record.url?scp=0018826878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018826878&partnerID=8YFLogxK

U2 - 10.1007/BF00254034

DO - 10.1007/BF00254034

M3 - Article

C2 - 7389058

AN - SCOPUS:0018826878

VL - 4

SP - 129

EP - 132

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -